Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic
Conclusions
Mass switch from IV to subcutaneous TCZ during the SARS-CoV-2 pandemic has been safe, effective, and well tolerated after 1 year of follow-up.
Source: JCR: Journal of Clinical Rheumatology - Category: Rheumatology Tags: Original Articles Source Type: research
More News: Actemra | Arthritis | Headache | Migraine | Pandemics | Polymyalgia Rheumatica | Rheumatoid Arthritis | Rheumatology | SARS | Scleroderma | Study